Contributions of the European trials (European randomized screening group) in computed tomography lung cancer screening
- PMID: 25635703
- DOI: 10.1097/RTI.0000000000000135
Contributions of the European trials (European randomized screening group) in computed tomography lung cancer screening
Abstract
Lung cancer is the leading cause of cancer-related death worldwide. In 2011, the largest lung cancer screening trial worldwide, the US National Lung Screening Trial, published a 20% decrease in lung cancer-specific mortality in the computed tomography (CT)-screened group, compared with the group screened by chest x-ray. On the basis of this trial, different US guidelines recently have recommended CT lung cancer screening. However, several questions regarding the implementation of lung cancer screening need to be answered. In Europe, several lung cancer screening trials are ongoing. It is planned to pool the results of the lung cancer screening trials in European randomized lung cancer CT screening (EUCT). By pooling of the data, EUCT hopes to be able to provide additional information for the discussion of some important issues regarding the implementation of lung cancer screening by low-dose CT, including: the determination of the optimal screen population, the comparison between a volume-based and diameter-based nodule management protocol, and the determination of optimal screen intervals.
Similar articles
-
[Lung cancer screening - where are we in 2013?].Zentralbl Chir. 2013 Oct;138 Suppl 1:S11-5. doi: 10.1055/s-0033-1350855. Epub 2013 Oct 22. Zentralbl Chir. 2013. PMID: 24150850 Review. German.
-
Lung cancer screening: the radiologist's perspective.Semin Respir Crit Care Med. 2014 Feb;35(1):91-8. doi: 10.1055/s-0033-1363455. Epub 2014 Jan 30. Semin Respir Crit Care Med. 2014. PMID: 24481763 Review.
-
Lung cancer screening and management.Minerva Med. 2015 Dec;106(6):339-54. Epub 2015 Nov 25. Minerva Med. 2015. PMID: 26605556 Review.
-
Screening for lung cancer: what have we learned?AJR Am J Roentgenol. 2014 Mar;202(3):530-5. doi: 10.2214/AJR.13.11540. AJR Am J Roentgenol. 2014. PMID: 24555588 Review.
-
An Update on the European Lung Cancer Screening Trials and Comparison of Lung Cancer Screening Recommendations in Europe.J Thorac Imaging. 2019 Jan;34(1):65-71. doi: 10.1097/RTI.0000000000000367. J Thorac Imaging. 2019. PMID: 30325795 Review.
Cited by
-
Optimizing the lung cancer screening interval: the world is waiting.J Thorac Dis. 2016 Oct;8(10):E1369-E1370. doi: 10.21037/jtd.2016.10.25. J Thorac Dis. 2016. PMID: 27867631 Free PMC article. No abstract available.
-
Incidental Pulmonary Nodules - What Do We Know in 2022.Respiration. 2022;101(11):1024-1034. doi: 10.1159/000526818. Epub 2022 Oct 13. Respiration. 2022. PMID: 36228594 Free PMC article. Review.
-
The Effect of Lung Volume on the Size and Volume of Pulmonary Subsolid Nodules on CT: Intraindividual Comparison between Total Lung Capacity and Tidal Volume.Taehan Yongsang Uihakhoe Chi. 2021 Nov;82(6):1534-1544. doi: 10.3348/jksr.2021.0141. Epub 2021 Oct 18. Taehan Yongsang Uihakhoe Chi. 2021. PMID: 36238880 Free PMC article.
-
Challenges and research opportunities for lung cancer screening in China.Cancer Commun (Lond). 2018 Jun 7;38(1):34. doi: 10.1186/s40880-018-0305-0. Cancer Commun (Lond). 2018. PMID: 29880036 Free PMC article.
-
Implementing lung cancer screening in the real world: opportunity, challenges and solutions.Transl Lung Cancer Res. 2015 Aug;4(4):353-64. doi: 10.3978/j.issn.2218-6751.2015.07.14. Transl Lung Cancer Res. 2015. PMID: 26380176 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical